Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of an Exclusive License: The Development of an Anti-GPC3 Chimeric Antigen Receptor (CAR) Based on HN3 for the Treatment of Human Cancers Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before June 2, 2016 will be considered.
View Prospective Grant of Exclusive License: AAV-Mediated Aquaporin Gene Transfer To Treat Sjögren's Syndrome Only written comments and/or applications for a license that are received by the National Institute of Dental and Craniofacial Research, Office of Technology Transfer and Innovation Access on or before May 16, 2016 will be considered.
View Prospective Grant of Exclusive License: The Development of Anti-CD70 Chimeric Antigen Receptors (CARs) for the Treatment of Chronic Myelogenous Leukemia Only written comments and/or applications for a license which are received by the Technology Transfer Center at the National Cancer Institute on or before May 9, 2016 will be considered.
View Prospective Grant of Exclusive License: Development of the CB1/iNOS Series of Compounds as a Therapeutic To Treat System Sclerosis, Scleroderma, and Other Skin Fibrotic Diseases in Humans Only written comments and/or applications for a license which are received by the Technology Advancement Office, The National Institute of Diabetes and Digestive and Kidney Diseases on or before May 4, 2016 will be considered.
View Prospective Grant of Exclusive License: The Development of MRI-1569, MRI-2213 and MRI-2214 as a Therapeutic To Treat Obesity, Diabetes, Fatty Liver Disease and Liver Fibrosis Only written comments and/or applications for a license which are received by the Technology Advancement Office, The National Institute of Diabetes and Digestive and Kidney Diseases on or before May 4, 2016 will be considered.
View Prospective Grant of Start-up Exclusive License: Therapeutics and PMA-Approved Diagnostics for Alzheimer's Disease (intranasal delivery), Parkinson's Disease, Neuropathy,Neuropathic Pain, Peripheral Neuropathy, Diabetic Neuropathy, Neurapraxia, Axonotmesis and Neurotmesis Only written comments and/or applications for a license which are received by NINDS Technology Transfer on or before April 25, 2016 will be considered.
View Prospective Grant of an Exclusive Patent License for Commercialization: Boron Neutron Capture Therapy for Brain Tumors Only written comments and/or applications for a license that are received by NIH at the address indicated below on or before April 21, 2016 will be considered.
View Prospective Grant of an Exclusive Patent License for Commercialization: Boron Neutron Capture Therapy for Skin Cancer Only written comments and/or applications for a license that are received by NIH at the address indicated below on or before April 21, 2016 will be considered.
View Prospective Grant of Exclusive License: Development of 5T4 Antibodies in Human Cancer Therapeutics and Diagnostics Only written comments and/or applications for a license which are received by the Technology Transfer Center at the National Cancer Institute on or before April 19, 2016 will be considered.
View Prospective Grant of Start-Up Exclusive License: Therapeutics for Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Certain Other CNS Disorders Only written comments and/or applications for a license which are received by NINDS Technology Transfer on or before April 19, 2016 will be considered.
View Prospective Grant of Exclusive License: Development and Commercialization of Cancer Immunotherapy Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 6, 2016 will be considered.
View Prospective Grant of Exclusive License: Production of Attenuated Respiratory Syncytial Virus Vaccines Only written comments and/or application for a license which are received by the National Institute of Allergy and Infectious Diseases, Technology Transfer and Intellectual Property Office on or before March 8, 2016. will be considered.
View Prospective Grant of Exclusive License: Development of In Vitro Diagnostics for the Detection of Diseases or Pathogenic Agents Only written comments or applications for a license (or both) which are received by the Technology Advancement Office, NIDDK, on or before March 3, 2016 will be considered.
View Announcement of Requirements and Registration for the “My Preparedness Story: Staying Healthy and Resilient” Video Challenge Challenge begins on January 4, 2016, and ends on March 28, 2016, 11 p.m. EST. ASPR staff will judge eligible submissions and select semifinalists April 4-8, 2016. The general public will rate the semifinalists' videos April 11-22, 2016. The winners will be notified and announced no later than May 9, 2016. ASPR will announce timeline changes by amending this Federal Register notice.
View Prospective Grant of an Exclusive Start-Up Option License: Potent and Selective Analogues of Monamine Transporters; Methods of Making; and Uses Thereof Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before January 6, 2016 will be considered.
View Prospective Grant of Exclusive License: Development of a Small Molecule Farnesoid X Receptor Inhibitor Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before January 4, 2016 will be considered.
View Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Development and Commercialization of Aza-Epoxy Guaiane Derivatives for Treatment of Renal Cancer Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before December 22, 2015 will be considered.
View Prospective Grant of Exclusive License: Development of In Vitro Diagnostics for the Detection of Diseases or Pathogenic Agents Only written comments or applications for a license (or both) which are received by the Technology Advancement Office, NIDDK, on or before December 7, 2015 will be considered.
View Prospective Grant of Exclusive License: Development of Cripto-1 Point of Care (POC) Tests and Kits for the Detection of Cancer Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before December 1, 2015 will be considered.
View Prospective Grant of Exclusive License: Development of Therapeutics To Treat Brain Injury and Neurodegenerative Disease Only written comments or applications for a license (or both) which are received by the Technology Advancement Office of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) on or before November 20, 2015 will be considered.
View Prospective Grant of Exclusive License: Development of Therapeutics To Treat Obesity, Type 2 Diabetes, Fatty Liver Disease, and Liver Fibrosis in Humans Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 12, 2015 will be considered.
View Announcement of Requirements and Registration for the Open Science Prize February 29, 2016: Phase I submissions due
View Prospective Grant of a Start-up Exclusive Commercial License Agreement: Development of MHC Class II Restricted T Cell Epitopes From the Cancer Antigen, NY ESO-1, for the Treatment of Human Cancers Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 19, 2015 will be considered.
View Prospective Grant of Exclusive License: Analytical Instruments Utilizing Condensation Particle Counters for the Detection and Analysis of Small Aerosol Particles Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before November 2, 2015 will be considered.
View Prospective Grant of Start-Up Exclusive License: Differential Expression of Molecules Associated With Acute Stroke Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 19, 2015 will be considered.